Amgen NSCLC Data Could Give Lumakras Boost As Competition Looms

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Mirati’s adagrasib is expected to win an FDA lung cancer nod, while also showing better data in pancreatic and colorectal cancer, making it more important for Lumakras to show strength in NSCLC.

Amgen announced longer-term data for Lumakras in NSCLC • Source: Alamy

Amgen, Inc. KRAS inhibitor Lumakras (sotorasib)’s market position stands to gain from two-year follow-up data from the company’s pivotal study in non-small cell lung cancer showing continued benefit on survival. Longer-term survival data could help bolster Amgen’s commercial case for its drug as it gears up for potentially stiff competition from Mirati Therapeutics, Inc.’s adagrasib, a competing drug in the same class that is widely expected to get US Food and Drug Administration approval and has shown better data than Lumakras in two other key KRAS-mutated cancers.

Amgen presented two-year follow-up data from the Phase I/II CodeBreaK 100 study in patients with KRAS G12C-mutated advanced non-small cell...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D